Janelle is Managing Editor of Custom Content. She previously worked in both publications and marketing/advertising in the medical communications field, with a focus on pharmaceuticals. Originally from New Jersey, Janelle attended Miami University for undergrad and is now pursuing a Masters in Publishing and Writing at Emerson College in Boston, Massachusetts, where she currently resides. In her spare time, Janelle enjoys watching films and cooking.
Latest from Janelle Hart
Roman Thomas, co-founder and CEO of DISCO Pharmaceuticals, outlines how the company’s surfaceome technology could disrupt drug discovery in oncology.
At the 2024 BIO International Convention, In Vivo spoke with Secarna Pharmaceuticals' CEO Alexander Gebauer about how the biotech's next-gen antisense oligonucleotide technology aims to benefit patients across multiple indications.
Roman Thomas, co-founder and CEO of DISCO Pharmaceuticals, outlines how the company’s surfaceome technology could disrupt drug discovery in oncology.
In Vivo sat down with Benjamin Hadida, CEO of Exeliom, at the 2024 BIO International Convention to discuss how the company is using its first-in-class drug candidate to improve therapeutic responsiveness in immuno-oncology, immuno-inflammation and rare disease.
This is the article description.
At the 2024 BIO International Convention, In Vivo spoke with Secarna Pharmaceuticals' CEO Alexander Gebauer about how the biotech's next-gen antisense oligonucleotide technology aims to benefit patients across multiple indications.